NCT04318717招募中2 期
Adjuvant Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Local tumor control rate
研究概览
简要总结
This is an open-label, single center, one cohort, non-randomized, phase II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect will be compared with historical radiation therapy-alone control data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed mucosal melanoma that has undergone surgical resection. Patient must not have received prior radiation therapy within the area of interest.
- •At least 16 years of age.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 70%)
- •Normal bone marrow and organ function as defined below:
- •Absolute neutrophil count ≥ 1,200/mcL
- •Platelets ≥ 100,000/mcL
- •Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN)
- •AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- •Creatinine clearance > 30 mL/min by Cockcroft-Gault
- •The effects of pembrolizumab on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and 6 months after last dose of pembrolizumab. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 6 months after last dose of pembrolizumab.
- •Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
排除标准
- •A history of other malignancy with the exception of malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease.
- •Received radiation therapy within the area of interest.
- •Currently receiving any other investigational agents.
- •Metastatic disease.
- •A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or other agents used in the study.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. The use of up to 10 mg/day of prednisone or equivalent is approved and does not exclude the patient from the trial.
- •Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, > 10 mg of prednisone per day, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. The use of up to 10 mg/day of prednisone or equivalent is approved and does not exclude the patient from the trial.
- •Has a history of (non-infectious) pneumonitis/Interstitial lung disease that required maintenance steroids (>10 mg of prednisone) or current pneumonitis/interstitial lung disease.
- •Has received a live vaccine or live-attenuated vaccination within 30 days of planned treatment start. Administration of killed vaccines is allowed.
- •Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
- •Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
研究组 & 干预措施
Pembrolizumab + Hypofractionated radiation therapy
Experimental
- Pembrolizumab will be given intravenously over 30 minutes (-5/+10 minutes) at a dose of 200 mg on an outpatient basis on Day 1 of each 21-day cycle for a total of up to 12 months (17 cycles).
- Hypofractionated radiation therapy may be given at any point during the first 2 cycles of pembrolizuimab. It should begin within 90 days of surgical resection. Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) are to be used exclusively. IMRT or IMPT will be delivered twice per week in five fractions of 6 Gy given over 2.5 weeks totaling 30 Gy.
干预措施: Pembrolizumab (Drug)
Pembrolizumab + Hypofractionated radiation therapy
Experimental
- Pembrolizumab will be given intravenously over 30 minutes (-5/+10 minutes) at a dose of 200 mg on an outpatient basis on Day 1 of each 21-day cycle for a total of up to 12 months (17 cycles).
- Hypofractionated radiation therapy may be given at any point during the first 2 cycles of pembrolizuimab. It should begin within 90 days of surgical resection. Intensity modulated radiation therapy (IMRT) or intensity modulated proton therapy (IMPT) are to be used exclusively. IMRT or IMPT will be delivered twice per week in five fractions of 6 Gy given over 2.5 weeks totaling 30 Gy.
干预措施: Hypofractionated radiation therapy (Radiation)
结局指标
主要结局
Local tumor control rate
时间窗: 1 year after completion of treatment (estimated to be 2 years)
Tumor control rate is defined as the percentage of subjects at 12 months who are free of local recurrence, regional recurrence, distant recurrence, second primary cancer, or death.
Local tumor control rate
时间窗: 1 year after completion of treatment (estimated to be 2 years)
Tumor control rate is defined as the percentage of subjects at 12 months who are free of local recurrence, regional recurrence, distant recurrence, second primary cancer, or death.
次要结局
- Number of treatment discontinuations due to treatment-related adverse events(Through end of treatment (estimated to be 1 year))
- Relapse-free survival (RFS)(At 3 years after completion of treatment (estimated to be 4 years))
- Distant metastasis-free survival(At 3 years after completion of treatment (estimated to be 4 years))
- Overall survival(At 3 years after completion of treatment (estimated to be 4 years))
- Number of treatment-related grade 3 or greater adverse events(Baseline through 90 days after end of treatment (estimated to be 15 months))
- Number of treatment discontinuations due to treatment-related adverse events(Through end of treatment (estimated to be 1 year))
- Relapse-free survival (RFS)(At 3 years after completion of treatment (estimated to be 4 years))
- Distant metastasis-free survival(At 3 years after completion of treatment (estimated to be 4 years))
- Overall survival(At 3 years after completion of treatment (estimated to be 4 years))
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer PatientsStage IIIA Non-small Cell Lung CancerNCT03053856Samsung Medical Center37
进行中（未招募）
2 期
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO TrialNeoadjuvantImmunotherapySarcoma,Soft TissueRadiation TherapyNCT06128863Maria Sklodowska-Curie National Research Institute of Oncology40
已完成
2 期
Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial CancerEndometrial NeoplasmsNCT03276013Vall d'Hebron Institute of Oncology48
终止
2 期
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell TumorsGerm Cell NeoplasmsTesticular NeoplasmsNon Seminomatous Germ Cell TumorsMediastinal NeoplasmsGenital Neoplasms, MaleGenital Neoplasms, FemaleOvarian NeoplasmsNCT02499952Nasser Hanna, M.D.12
进行中（未招募）
2 期
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal CancerMetastatic CancerColorectal CancerNCT03475004University of Colorado, Denver53